Improving the measurement properties of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): deriving a valid measurement total for the calculation of change.

Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, Trajectories of Outcome in Neurological Conditions-ALS, Rasch outcome measurement, disability

Journal

Amyotrophic lateral sclerosis & frontotemporal degeneration
ISSN: 2167-9223
Titre abrégé: Amyotroph Lateral Scler Frontotemporal Degener
Pays: England
ID NLM: 101587185

Informations de publication

Date de publication:
01 Mar 2024
Historique:
medline: 1 3 2024
pubmed: 1 3 2024
entrez: 1 3 2024
Statut: aheadofprint

Résumé

The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score is a widely used measure of functional status in Amyotrophic Lateral Sclerosis/Motor Neuron Disease (ALS), but recent evidence has raised doubts about its validity. The objective was to examine the measurement properties of the ALSFRS-R, aiming to produce valid measurement from all 12 scale items. Longitudinal ALSFRS-R data were collected between 2013-2020 from 1120 people with ALS recruited from 35 centers, together with other scales in the Trajectories of Outcomes in Neurological Conditions-ALS (TONiC-ALS) study. The ALSFRS-R was analyzed by confirmatory factor analysis (CFA), Rasch Analysis (RA) and Mokken scaling. No definite factor structure of the ALSFRS-R was confirmed by CFA. RA revealed the raw score total to be invalid even at the ordinal level because of multidimensionality; valid interval level subscale measures could be found for the Bulbar, Fine-Motor and Gross-Motor domains but the Respiratory domain was only valid at an ordinal level. All four domains resolved into a single valid, interval level measure by using a bifactor RA. The smallest detectable difference was 10.4% of the range of the interval scale. A total ALSFRS-R ordinal raw score can lead to inferential bias in clinical trial results due to its non-linear nature. On the interval level transformation, more than 5 points difference is required before a statistically significant detectable difference can be observed. Transformation to interval level data should be mandatory in clinical trials.

Sections du résumé

BACKGROUND UNASSIGNED
The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score is a widely used measure of functional status in Amyotrophic Lateral Sclerosis/Motor Neuron Disease (ALS), but recent evidence has raised doubts about its validity. The objective was to examine the measurement properties of the ALSFRS-R, aiming to produce valid measurement from all 12 scale items.
METHOD UNASSIGNED
Longitudinal ALSFRS-R data were collected between 2013-2020 from 1120 people with ALS recruited from 35 centers, together with other scales in the Trajectories of Outcomes in Neurological Conditions-ALS (TONiC-ALS) study. The ALSFRS-R was analyzed by confirmatory factor analysis (CFA), Rasch Analysis (RA) and Mokken scaling.
RESULTS UNASSIGNED
No definite factor structure of the ALSFRS-R was confirmed by CFA. RA revealed the raw score total to be invalid even at the ordinal level because of multidimensionality; valid interval level subscale measures could be found for the Bulbar, Fine-Motor and Gross-Motor domains but the Respiratory domain was only valid at an ordinal level. All four domains resolved into a single valid, interval level measure by using a bifactor RA. The smallest detectable difference was 10.4% of the range of the interval scale.
CONCLUSION UNASSIGNED
A total ALSFRS-R ordinal raw score can lead to inferential bias in clinical trial results due to its non-linear nature. On the interval level transformation, more than 5 points difference is required before a statistically significant detectable difference can be observed. Transformation to interval level data should be mandatory in clinical trials.

Identifiants

pubmed: 38426231
doi: 10.1080/21678421.2024.2322539
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-10

Auteurs

Carolyn A Young (CA)

Walton Centre NHS Foundation Trust, Liverpool, UK.
Department of Pharmacology and Therapeutics, University of Liverpool, UK.

Amina Chaouch (A)

Greater Manchester Centre for Clinical Neurosciences, Salford, UK.

Christopher J Mcdermott (CJ)

Sheffield Institute for Translational Neuroscience, Sheffield, UK.

Ammar Al-Chalabi (A)

Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, King's College London, London, UK.
Department of Neurology, King's College Hospital, London, UK.

Suresh K Chhetri (SK)

Lancashire Teaching Hospital, Preston, UK.

Kevin Talbot (K)

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Andrea Malaspina (A)

UCL Queen Square Institute of Neurology, London, UK, and.

Roger Mills (R)

Walton Centre NHS Foundation Trust, Liverpool, UK.
Department of Pharmacology and Therapeutics, University of Liverpool, UK.

Alan Tennant (A)

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK.

Classifications MeSH